- AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1
- FDA Orders Important Safety Labeling Changes for Addyi Regarding Alcohol Consumption
- Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes
- Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
- Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma
- Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1
- Novo Nordisk Files for US FDA Approval of Oral Semaglutide for Blood Sugar Control and Cardiovascular Risk Reduction in Adults with Type 2 Diabetes
- Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
- Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
- Data From GARNET Study Indicates Robust Activity of Dostarlimab in Patients with Advanced or Recurrent Endometrial Cancer
- Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
- Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole
- Moleculin Files with FDA for Expedited Approval Pathway for Annamycin
- Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant
- Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain